By Vin Gurrieri

Law360, New York (February 21, 2012, 6:04 PM ET) -- Generic pharmaceutical manufacturer Apotex Inc. launched a suit in Delaware Thursday accusing Allergan Inc. and two Japanese drug manufacturers of pinkeye medication Zymar of creating a monopoly over the medication and creating a new version of the treatment to eliminate generic competition.

The suit accuses Allergan, Senju Pharmaceutical Co. Ltd. and Kyorin Pharmaceutical Co. Ltd. of violating the Sherman and Clayton Acts by creating a functionally similar version of Zymar containing a slightly different concentration of the antibiotic gatifloxacin in order to maintain its dominant market...